hotspot -WSS

hotspot

author：knowledge 2025-09-02 09:37:17 - browse：34953

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Senator probes 340B programs at Cleveland Clinic, Bon Secours

explore

WSS

Medicare drug price negotiation program allowed for now

Data show record exodus of life scientists from academia

What health policies could hitch a ride on a spending bill?

Sudafed saga points to U.S. issues with evaluating older drugs

After a drawn out lobbying fight, ARPA

Biogen shutters digital health group, ends Apple study, in cost cutting move

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Address the ethical violations that led to 'Three Identical Strangers'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Weight loss drugs should be covered by insurers, AMA says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA seeks to regulate lab

Guidelines to prevent youth baseball injuries need more muscle

WHO recommends dropping component of many flu vaccines

Continuity nursing helped my family in our darkest PICU moments

Carbon Health diabetes program, a test of data

focus

Senator probes 340B programs at Cleveland Clinic, Bon Secours

How the Dana

Cigna to pay $172 million to settle Medicare Advantage fraud probe

FDA advisers vote against ALS treatment from BrainStorm

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Medicare’s new pay boost for primary care is angering specialists

explore

entertainment

focus

Wikipedia